NEW YORK, April 20, 2018 -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed Cancer Genetics, Inc. (“Cancer Genetics” or the “Company”) (NASDAQ:CGIX) and certain of its officers, on behalf of shareholders who purchased Cancer Genetics securities between March 23, 2017 and April 2, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/cgix.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Cancer Genetics had ineffective disclosure controls and internal controls over financial reporting; and (2) consequently, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/cgix or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Cancer Genetics you have until June 4, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]


AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 



